Introduction {#Sec1}
============

Endometrial carcinoma (EC) is one of the most common gynecological malignancies \[[@CR1]\]. There are various histologic subtypes of EC including endometrioid, serous, clear cell, mucinous carcinoma and carcinosarcoma. These have been historically categorized into two major groups (type I and type II cancers) \[[@CR2]\]. Endometrioid cancers are typically hormone (estrogen) driven and they are strongly linked to estrogen exposure \[[@CR3]\]. On the other hand, recent evidence suggest that serous cancers may also be associated with hormone exposure \[[@CR4], [@CR5]\]. Progesterone and related compounds halts estrogen driven proliferation and they can be used in the therapy for low grade endometrioid cancers \[[@CR6]\]. Androgens also display anti-proliferative effect in normal endometrium and therefore can theoretically play a role similar to progestins \[[@CR7]\]. Recent studies revealed that loss of androgen receptor (AR) expression was found to be with poor survival in EC \[[@CR8]\]. On the other hand, AR expression may serve as a potential therapeutic target in EC. Therefore, in the present study we aimed to evaluate the expression of AR in EC in our population and its association with various clinic-pathologic parameters.

Main text {#Sec2}
=========

Case selection {#Sec3}
--------------

Total 103 cases of endometrial carcinoma were selected from records of pathology department archives. All patients underwent surgeries at Liaquat National hospital, Karachi from January 2012 till December 2017 over a period of 6 years. The study was approved by research and ethical review committee of Liaquat National Hospital and informed written consent was taken from all patients at the time of surgery. Hematoxylin and eosin stained slides and paraffin blocks were retrieved and new sections were cut where necessary. Slides of all cases were reviewed by two senior histopathologists and pathologic characteristics like histologic type, tumor grade, T-stage, lymphovascular invasion were evaluated. Moreover, representative tissue blocks of 89 cases were available for AR immunohistochemistry.

Immunohistochemistry {#Sec4}
--------------------

Androgen receptor IHC was performed using DAKO EnVision method using monoclonal mouse anti-human androgen receptor; clone AR441 according to manufacturer's protocol (dilution of 1:50). Nuclear staining for AR was both quantitatively and qualitatively evaluated. Hormone receptor IHC scoring was based on the Liverpool endometrial steroid quick score with a final score out of 12 calculated by multiplying the proportion of positive tumor nuclei (1--10% = 1, 11--20% = 2, 21--40% = 3, \> 40% = 4) by the staining intensity (0 = no staining, 1 = weak, 2 = moderate, 3 = strong). Scores of 1--4 were characterized as low, scores of 5--8 were considered moderate, and scores of 9--12 were classified as high (Fig. [1](#Fig1){ref-type="fig"}).Fig. 1Androgen receptor expression in endometrial carcinoma

Statistical analysis {#Sec5}
--------------------

Statistical package for social sciences (SPSS 21) was used for data compilation and analysis. Mean and standard deviation were calculated for quantitative variables. Frequency and percentage were calculated for qualitative variables. Fisher exact test was applied to determine association. P value ≤ 0.05 was taken as significant.

Demographic patient's profile {#Sec6}
-----------------------------

Table [1](#Tab1){ref-type="table"} shows demographic profile of patients. Mean age of the patients was 56.34 years (+ 9.79). 81.6% patients were post menopausal at the time of presentation. Most common histologic subtype of EC was endometrioid (87/103, 84.5%) followed by serous (9/103, 8.7%) and carcinosarcoma (6/103, 5.8%). Most patients had more than half of myometrial invasion (59/103, 57.3%), while cervical invasion, adnexal involvement and nodal metastasis was present in 26/103 (25.2%), 11/103 (10.7%) and 7/103 (6.8%) cases respectively. 89/103 (86.4%) cases were at stage T1/T2 while 71/103 (68.9%) were correspondingly at FIGO stage 1 (Table [1](#Tab1){ref-type="table"}).Table 1Demographic profile of patients involved in the study (n = 103)n (%)Age (years)56.34 ± 9.79Menopausal status Pre menopausal19 (18.4) Post menopausal84 (81.6)Histological type Endometrioid87 (84.5) Serous9 (8.7) Clear cell1 (1) Carcinosarcoma6 (5.8)Grade Grade I41 (39.8) Grade II40 (38.8) Grade III22 (21.4)Myometrial invasion Limited to endometrium6 (5.8) Less than half of myometrium38 (36.9) More than half of myometrium59 (57.3)Cervical invasion Present26 (25.2) Absent77 (74.8)Adnexal involvement Present11 (10.7) Absent92 (89.3)Nodal status N096 (93.2) N16 (5.8) N21 (1)Lymphovascular invasion Present8 (7.8) Absent95 (92.2)T stage T172 (69.9) T217 (16.5) T310 (9.7) T44 (3.9)FIGO stage Stage IA40 (38.8) Stage IB31 (30.1) Stage II18 (17.5) Stage IIIA8 (7.8) Stage IIIB2 (1.9) Stage IV4 (3.9)

Androgen receptor expression in endometrial carcinoma {#Sec7}
-----------------------------------------------------

18/89 (20.2%) cases of EC showed positive AR expression. On the other hand, low, moderate and high AR expression was noted in 7/89 (7.9%), 10/89 (11.2%) and 1/89 (1.1%) cases respectively. 15/77 (19.48%) of endometrioid cancers and 3/7 (42.28%) cases of serous carcinoma showed AR expression; while none of the cases of clear cell or carcinosarcoma revealed AR expression. No significant association of AR expression with various clinicopathologic features of EC was noted (Table [2](#Tab2){ref-type="table"}).Table 2Association of androgen receptor expression with clinicopathologic features of endometrial carcinoman (%)P valueNegative (n = 71)Low (n = 7)Moderate (n = 10)High (n = 1)Total (n = 89)Menopausal status Pre menopausal14 (19.7)2 (28.6)1 (10)0 (0)17 (19.1)0.743 Post menopausal57 (80.3)5 (71.4)9 (90)1 (100)72 (80.9)Histological type Endometrioid62 (87.3)5 (71.4)10 (100)0 (0)77 (86.5)0.117 Serous4 (5.6)2 (28.6)0 (0)1 (100)7 (7.9) Clear cell1 (1.4)0 (0)0 (0)0 (0)1 (1.1) Carcinosarcoma4 (5.6)0 (0)0 (0)0 (0)4 (4.5)Grade Grade I28 (39.4)3 (42.9)4 (40)0 (0)35 (39.3)0.293 Grade II30 (42.3)2 (28.6)6 (60)0 (0)38 (42.7) Grade III13 (18.3)2 (28.6)0 (0)1 (100)16 (18)Myometrial invasion Limited to endometrium4 (5.6)0 (0)2 (20)0 (0)6 (6.7)0.518 \< 1/2 of myometrium26 (36.6)3 (42.9)2 (20)0 (0)31 (34.8) \> 1/2 of myometrium41 (57.7)4 (57.1)6 (60)1 (100)52 (58.4)Cervical invasion Present17 (23.9)3 (42.9)3 (30)0 (0)23 (25.8)0.581 Absent54 (76.1)4 (57.1)7 (70)1 (100)66 (74.2)Nodal status N067 (94.4)6 (85.7)10 (100)1 (100)84 (94.4)0.499 N13 (4.2)1 (14.3)0 (0)0 (0)4 (4.5) N21 (1.4)0 (0)0 (0)0 (0)1 (1.1)Lymphovascular invasion Present5 (7)1 (14.3)0 (0)0 (0)6 (6.7)0.529 Absent66 (93)6 (85.7)10 (100)1 (100)83 (93.3)T stage T151 (71.8)4 (57.1)6 (60)1 (100)62 (69.7)0.607 T210 (14.1)3 (42.9)3 (30)0 (0)16 (18) T37 (9.9)0 (0)1 (10)0 (0)8 (9) T43 (4.2)0 (0)0 (0)0 (0)3 (3.4)FIGO stage Stage IA28 (39.4)2 (28.6)4 (40)0 (0)34 (38.2)0.853 Stage IB22 (31)2 (28.6)2 (20)1 (100)27 (30.2) Stage II11 (15.5)3 (42.9)3 (30)0 (0)17 (19.1) Stage IIIA6 (8.5)0 (0)1 (10)0 (0)7 (7.9) Stage IIIB1 (1.4)0 (0)0 (0)0 (0)1 (1.1) Stage IV3 (4.2)0 (0)0 (0)0 (0)3 (3.4)Fisher exact test appliedP value ≤ 0.05, considered as significant

In the present study, we aimed to evaluate the AR expression in endometrial cancers and found that a significant proportion of endometrial cancers especially serous cancers exhibit AR expression, that may have clinical and therapeutic significance.

Variable expression of AR was seen in previous studies. Sasaki et al. reported 21% expression of AR \[[@CR9]\]; on the other hand, as high as 89% AR expression was detected in another study \[[@CR10]\]. Some studies reported degree of differentiation/grade of EC to be inversely associated with AR expression \[[@CR11]\]; however, no such association was noted in our study. In the prior studies most of the work focused on endometrioid EC, as it seems to arise as a result of hormonal drive. In a recent study, it was noted that 70% of serous cancers and 50% of carcinosarcoma also show AR expression and high levels of AR expression was noted in half of serous carcinoma \[[@CR12]\]. These findings correlate with results of our study as we found 42.8% serous cancers to express AR, while high AR expression was also noted in serous carcinoma. Some studies also revealed association of AR expression with good prognostic features and better disease free survival \[[@CR13]\]; however, we didn't found any significant association of AR expression with various pathologic parameters like tumor stage and nodal metastasis.

From a clinical standpoint, it is important to know if AR IHC expression can identify a subset of EC that can benefit from anti-androgen therapy. Recent evidence supports this speculation that androgen receptor antagonism can be a therapeutic option in EC \[[@CR14], [@CR15]\]. This becomes especially important in high grade endometrioid and serous cancers in which endocrine (ER/PR) therapeutic option is not available. In our study we found a high frequency of serous cancers to express AR.

Limitations {#Sec8}
===========

One of the major limitations of our study was lack of clinical follow up to elucidate AR expression with disease free survival and low number of cases of non-endometrioid cancer. Therefore, we suggest more large scale studies with clinical follow up to identify role of AR expression as prognostic marker in EC.
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